Dosing to stop in Phase III clinical study of tominersen following recommendation from an Independent Data Monitoring Committee (iDMC) No new safety signals were identified for tominersen in the iDMC’s review Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1... Read more
First Phase III study to show that a cancer immunotherapy improves disease-free survival in people with resectable early stage lung cancer compared to best supportive care Treating lung cancer early, before it has spread, may help prevent the disease from returning and therefore provide the best opportunity for a cure Data will be submitted to... Read more
cobas® pure integrated solutions brings together three diagnostic technologies1 on a single platform to optimise space and resources in small to medium laboratory settings With a footprint of just two square meters, this new analyser provides small to medium sized labs with access to more than 230 diagnostic tests2 across a wide-range of disease areas... Read more
All proposals of the Board of Directors approved Christoph Franz re-elected as Chairman of the Board of Directors; all current Board members re-elected 34th consecutive dividend increase to CHF 9.10 per share Basel, 16 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of... Read more
The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission Accurate detection and differentiation of SARS-CoV-2 mutations can help assess the spread of circulating variants and monitor their potential impact on therapeutics, vaccines and public health interventions Periodic assessments against emerging variants have... Read more
Basel, 15 March 2021 Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021 GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample GenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the... Read more
For patients living in areas with limited healthcare resources, WHO prequalification ensures access to the highest quality diagnostics Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs Roche’s Global Access Program provides innovative diagnostic solutions improving disease and patient management for those most in need Basel, 11... Read more
The REMDACTA clinical trial of Actemra/RoActemra plus Veklury did not meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia or its key secondary endpoints compared to Veklury alone Roche will submit the REMDACTA results to a peer-reviewed journal Basel, 11 March 2021 – Roche (SIX: RO, ROG; OTCQX:... Read more
Basel, 8 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the company is voluntarily withdrawing the US indication for Tecentriq® (atezolizumab) in prior-platinum treated metastatic urothelial carcinoma (mUC, bladder cancer). This decision was made in consultation with the US Food and Drug Administration (FDA) as part of an industry-wide review of... Read more
Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threatening In a global study, Actemra/RoActemra reduced the rate of progressive loss of lung function in... Read more